Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
about
Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshopChildren's Oncology Group's 2013 blueprint for research: renal tumorsDeducing the stage of origin of Wilms' tumours from a developmental series of Wt1-mutant miceThe yin and yang of kidney development and Wilms' tumorsGenetic and chromosomal alterations in Kenyan Wilms Tumor.TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney.MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours.Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors.Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.Association of FOXM1 expression with tumor histology and prognosis in Wilms tumor: Potential for a new prognostic marker.Cancer subclonal genetic architecture as a key to personalized medicine.Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor.CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus.Biomarkers to detect Wilms tumors in pediatric patients: where are we now?Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.LINking microRNAs, kidney development, and Wilms tumorsThe stem and roots of Wilms' tumours.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationThe developmental programme for genesis of the entire kidney is recapitulated in Wilms tumour.The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.Biallelic DICER1 mutations occur in Wilms tumours.A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients.Germline mutations and somatic inactivation of TRIM28 in Wilms tumour.Genomics of adult and pediatric solid tumors
P2860
Q26829595-516E7E03-3275-461D-963B-4C615680886FQ27000449-8DC61BF5-BB05-40AC-B4A7-AC8028BC4785Q30660201-0BE48161-CF1A-4F78-8400-81A19480A5D0Q35173260-63DEE330-4CE1-4A13-877B-42FF945C690AQ36052678-E14A2DE9-9FB6-4074-A7E2-CE71C6BAE4FCQ36140638-A79BA7D3-F446-475E-8CC8-9196F4290F17Q36392072-29ABB73C-FDD0-4462-9836-FCB45991278FQ36611566-584BA8FD-B05D-4EB1-B083-2CE61CB44DF2Q36709112-6BEBC57D-F683-4015-BA05-AE758CDA4D9BQ37218003-A522FE8B-2AB9-49C1-A9E7-2125ACCABB2BQ37288367-527B616A-D6C4-4E21-B052-4AFE5DFA2141Q37448116-FDBAB40B-59EA-4942-B800-60DAB77636E6Q37639483-EDE81F5A-21B7-4A9B-8C5A-294DD6C75E48Q37660299-2C54F909-CB65-41E0-B1D1-12A072DF72B9Q38559338-A24DC492-C733-4135-BC01-35CB7E01B9C3Q38972223-123936C0-29E2-448A-AA25-22F7A9756CB8Q38998052-7BF76189-3033-4B1B-963E-819C1B6094E6Q39526191-F7AE04BE-03B7-4655-AF00-36F50E950C91Q41783611-2E2A0821-EDDF-418A-BC18-9FE374E04959Q41879186-9B70E2A6-9C52-459B-BFFA-B8A3F135DDBCQ42685351-6E2DA4E3-FF6C-4DD7-87F3-36C84D8612FDQ42995400-0475A563-720E-4396-9800-60453D614D58Q46977021-780B1D4E-4C7D-44A0-A2D0-D51CE73C3F69Q47773339-F2F34FC4-2E78-44F5-9FE7-D1FDC2471485Q49569330-908D2B7F-685B-4468-AF86-395DF4396EFBQ55262812-69333012-6785-4FC1-8922-7B042124CF57Q58804574-2E360102-3B1B-4379-9D7E-7E7C469B4F71
P2860
Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Clinically relevant subsets id ...... ildren's Oncology Group Study.
@ast
Clinically relevant subsets id ...... ildren's Oncology Group Study.
@en
type
label
Clinically relevant subsets id ...... ildren's Oncology Group Study.
@ast
Clinically relevant subsets id ...... ildren's Oncology Group Study.
@en
prefLabel
Clinically relevant subsets id ...... ildren's Oncology Group Study.
@ast
Clinically relevant subsets id ...... ildren's Oncology Group Study.
@en
P2093
P2860
P356
P1433
P1476
Clinically relevant subsets id ...... ildren's Oncology Group Study.
@en
P2093
Chiang-Ching Huang
Daniel M Green
E Cristy Ruteshouser
Elizabeth J Perlman
J Bruce Beckwith
Jeffrey S Dome
Lawrence Jennings
Norman Breslow
Paul E Grundy
Samantha Gadd
P2860
P304
P356
10.1593/NEO.12714
P577
2012-08-01T00:00:00Z